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GRowing an Epidermal Tumor
Wendy B. Bollag1,2,3,4,5,6 and Carlos M. Isales5,6,7
The glucocorticoid receptor (GR), a member of the nuclear hormone family of
transcription factors, has key physiological roles in many organs, including the
skin. In this issue, Latorre et al. demonstrate that mice lacking GR in the epidermis
exhibit increased vulnerability to chemical carcinogenesis. Evidence supporting an
involvement of GR signaling in physiological and pathophysiological processes in
skin is discussed.
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Glucocorticoids are used pharmacologi-
cally to treat multiple diseases, includ-
ing skin disorders, because of their
potent anti-inflammatory properties,
but these agents can have significant
adverse side effects, such as thinning/
atrophy of the skin, impaired wound
healing, and the development of
irreversible striae. However, the physio-
logical and pathophysiological effects of
these agents in skin are less well
understood.
Glucocorticoids function by binding
to the glucocorticoid receptor (GR), a
member of the nuclear hormone family
of transcriptional regulators. Upon bind-
ing their ligands, the nuclear hormone
receptors homodimerize and/or hetero-
dimerize and regulate transcription of
genes containing response elements in
their promoters. Nuclear receptor
ligands can also exert ‘‘non-genomic’’
(non-transcriptional) effects. These may
be mediated through alternate receptors
in some cases or via ‘‘transcriptional
repression’’ involving interference with
other transcription factors. For example,
GR can directly suppress nuclear factor-
kappa B (NF-kB) signaling to repress
NF-kB gene targets.
Accumulating evidence points to an
important role for GR in the physiologi-
cal regulation of epidermal structure and
function (reviewed in Perez (2011)).
Such support arises from studies
investigating the effects of targeted GR
overexpression in transgenic mice, as
well as global and tissue-specific GR
deletion in knockout and conditional
knockout mice. For example, Perez
et al. (2001) used the keratin 5 pro-
moter to target GR transgene expression
to basal epidermal keratinocytes in a
genetically manipulated mouse model,
the K5-GR mouse. These mice exhibited
defects at birth reminiscent of those
observed in patients with ectodermal
dysplasia disorders such as aplasia cutis
congenita (Perez et al., 2001). Thus,
these transgenic mice showed patches
of thinning or absent skin, particularly
on the cranium, as well as epidermal
desquamation and incomplete closure of
the fontanella and eyelids. In general,
the epidermis was hypoplastic, and in
some cases necrotic, with impaired hair
follicle development and scarce
eyebrows and vibrissae. Upon the appli-
cation of the phorbol ester tumor
promoter, 12-O-tetradecanoylphorbol
13-acetate (TPA), the epidermis of
wild-type mice developed hyperplasia
and expressed inflammatory cytokines
(Perez et al., 2001); this effect was
attenuated in K5-GR mice. In addition,
by electrophoretic mobility shift assay,
these mice also demonstrated reduced
basal NF-kB activity, consistent with the
ability of GR to induce transcriptional
repression. These results suggest that
GR has anti-proliferative and anti-
inflammatory effects in epidermal
keratinocytes in accord with the utility
of glucocorticoids in treating hyper-
proliferative and inflammatory skin
disorders. Similarly, Perez and collea-
gues (Sanchis et al., 2012) also showed
decreased keratinocyte migration
(in vitro and in vivo) and delayed
cutaneous skin wound healing in the
K5-GR mice, as well as a reduced infla-
mmatory response and immune cell
infiltration, again in agreement with the
impaired skin healing observed with
glucocorticoid treatment.
Results with global GR knockout
mice have also suggested the physiolo-
gical importance of this nuclear
hormone receptor in the epidermis. GR
knockout mice die perinatally owing to
a lack of lung surfaction (Perez, 2011),
but possibly also in part because of
impairment of the permeability barrier
in skin. Thus, these mice exhibit an in-
competent skin barrier and an abnormal
epidermal ultrastructure (Bayo et al.,
2008); keratinocytes isolated from
these mice demonstrated decreased
levels of keratinocyte differentiation
markers and increased epidermal
keratinocyte proliferation and apoptosis
in vitro (Bayo et al., 2008). (Intere-
stingly, mice expressing a dimerization
mutant GR showed normal embryonic
epidermal development and differen-
tiation (Bayo et al., 2008), suggesting
that monomeric GR exerts most of the
effects of this nuclear hormone receptor
in the epidermis.)
Recently, Perez and colleagues have
also generated an epidermal-specific
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conditional GR knockout mouse model
(Epi-GRKO) and have begun to charac-
terize its phenotype. These authors
found that the Epi-GRKO mice exhibit
a thickened epidermis, increased prolif-
eration (BrdU incorporation) in the epi-
dermis, and a more pronounced DNA
synthetic response to TPA treatment
(Sevilla et al., 2010). In addition, loss
of the GR in epidermal keratinocytes
results in skin barrier defects and cuta-
neous inflammation (Sevilla et al.,
2013), with features that are chara-
cteristic of inflammatory skin diseases
such as psoriasis and atopic dermatitis.
These features include hyperprolife-
ration, abnormal differentiation, impai-
red permeability barrier function, and
infiltration of macrophages and mast
cells. In the article reported in the
current issue, this same group (Latorre
et al., 2013) now reports that the Epi-
GRKO mice demonstrate an increased
susceptibility to epidermal tumori-
genesis in the traditional two-stage
model of skin carcinogenesis, in which
the epidermis is initiated with topical
application of the mutagen 12-dimethyl-
benz(a) anthracene and promoted
using TPA. The effect of the loss of
GR in keratinocytes on tumorigenesis
appeared to be the result of enhanced
proliferation and inflammation and
impaired differentiation in these Epi-
GRKO mice (Latorre et al., 2013). The
results are also consistent with the data
of Budunova et al. (2003), who showed
that K5-targeted overexpression of GR
suppressed TPA-promoted tumor forma-
tion in mice also possessing the v-Ha-ras
oncogene. Together, these results
suggest that both too little and too
much GR activity can result in patho-
logical consequences, indicating the
necessity of a precise regulation of
glucocorticoids and GR in the skin.
This interpretation is further sup-
ported by studies examining the regula-
tion of the expression of enzymes
involved in activating or inactivating
the physiological glucocorticoid, corti-
sol (corticosterone in rodents). Cortisol
(corticosterone) is produced by the
adrenal cortex upon stimulation of the
adrenal gland by the hypothalamic–
pituitary axis (HPA), although it should
be noted that there are reports that the
skin also expresses key components of
the HPA and can synthesize glucocorti-
coids (reviewed in Slominski et al.
(2007)). Active cortisol (corticosterone)
can be converted to inactive corti-
sone (or 11-dehydrocorticosterone in
rodents) by the activity of the enzyme
11b-hydroxysteroid dehydrogenase
type 2 (11HSD2) to decrease GR
activity, whereas 11b-hydroxysteroid
dehydrogenase type 1 (11HSD1) does
the opposite, metabolizing inactive
cortisone to active cortisol. Both of
these enzymes appear to be expressed
in the skin. 11HSD1 is decreased in
basal cell carcinoma (BCC), squamous
cell carcinoma (SCC), and seborrheic
keratosis (SK) compared with normal
human epidermis, whereas 11HSD2 is
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increased in BCC and SK but not in SCC
(Terao et al., 2013). Similarly, 11HSD1
is reduced (concomitant with an
increase in mitotic index) in the epider-
mis upon treatment with TPA. Over-
expression of 11HSD2 in keratinocytes
in vitro stimulates proliferation, as does
application of an 11HSD1 inhibitor
(Terao et al., 2013). These results are
consistent with the idea that cortisol/GR
signaling represses tumorigenesis such
that the decreased cortisol resulting from
reduced 11HSD1 and elevated 11HSD2
would be expected to promote tumor
formation.
Interestingly, GR signaling may also
participate in the aging process in skin.
Thus, the K5-GR mice exhibit features
similar to those observed in aged skin
(e.g., atrophy and decreased prolifera-
tion); together with the ability of
exogenous glucocorticoids to induce
skin atrophy, this result suggests the
possibility that skin aging could be
related to excess glucocorticoid/GR
activity. Indeed, Stewart and colleagues
(Tiganescu et al., 2013) have shown that
blocking 11HSD1, either with an
inhibitor or by deleting the gene in
11HSD1 knockout mice, prevents age-
related defects in skin structure and
function. Thus, the 11HSD1 knockout
mice show less dermal atrophy and more
dermal collagen with age, as well as
accelerated wound healing. An 11HSD1
inhibitor also enhances skin wound
healing in wild-type mice. In addition,
aged human and rodent skin both
demonstrate elevated 11HSD1 levels
and activity; the latter is also increased
in photoexposed relative to photopro-
tected skin (Tiganescu et al., 2013).
These results suggest a possible involve-
ment of cortisol/GR signaling in age- and
UV irradiation–induced changes in skin.
Finally, it should be noted that the
effects of glucocorticoids in the skin
may not be solely related to GR signal-
ing. Thus, cortisol (or corticosterone)
can also bind to and activate the miner-
alocorticoid receptor (MR), another
member of the nuclear hormone recep-
tor family. Indeed, serum cortisol (or
corticosterone) levels are actually much
higher than the levels of circulating
aldosterone, the physiologic mineralo-
corticoid. In classical mineralocorticoid-
responsive tissues such as the kidney,
the MR is protected from activation by
cortisol by attendant 11HSD2. How-
ever, without 11HSD2’s conversion to
inactive cortisone, cortisol is capable of
activating MR signaling. MR is known to
be expressed in the skin (reviewed in
Farman et al. (2010)), and targeted over-
expression of this receptor in the
epidermis produces epidermal thinn-
ing, premature permeability barrier
formation, and alopecia (Sainte Marie
et al., 2007). Interestingly, in a meta-
bolic syndrome mouse model chara-
cterized by insulin insensitivity, the
accumulation of visceral fat, and lipid
metabolic changes, a single exposure to
UV light results in increases in epider-
mal oxidative stress and inflammatory
markers similar to those changes
observed with aging (Nagase et al.,
2013). In these mice, not only are MR
levels upregulated but also antagonism
of this receptor with spironolactone
blocks the UV-induced aging-like skin
alterations (Nagase et al., 2013).
Too little and too
much glucocorticoid
receptor activity
have pathological
consequences in skin.
In conclusion, glucocorticoids are routi-
nely used pharmacologically in derma-
tology to treat several skin diseases, with
their therapeutic use limited by adverse
effects such as skin atrophy. On the
other hand, multiple and accumulating
lines of evidence suggest the importance
of the glucocorticoid cortisol and its
target receptor GR (and/or possibly
MR) in regulating normal skin structure
and function. In addition, data also
point to a possibly key role of cortisol/
GR signaling in the pathophysiology of
various skin disorders, including hyper-
proliferative inflammatory skin disorders
such as atopic dermatitis and psoriasis,
genetic skin diseases such as ectodermal
dysplasia/aplasia cutis congenital, and
the changes associated with metabolic
syndrome and chronological aging and
photoaging. Thus, it seems likely that
sustained research into this important
signaling system will continue to pro-
vide insights into physiological and
pathological processes in the skin
(Figure 1).
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Figure 1. Glucocorticoid receptor signaling and epidermal function. (a) The glucocorticoid (GC) cortisol
(corticosterone in rodents) binds to the glucocorticoid receptor (GR) to stimulate keratinocyte (KC) terminal
differentiation and to inhibit KC proliferation and migration through the modulation of various gene
targets with GC response elements in their promoters. Cortisone (11-dehydrocorticosterone) can be
converted by 11b-hydroxysteroid dehydrogenase 1 (11HSD1) to active cortisol (corticosterone); the activity
of 11HSD1 can be increased by chronological aging and photoaging. The reverse reaction resulting in the
inactivation of cortisol is catalyzed by 11b-hydroxysteroid dehydrogenase 2 (11HSD2). Cortisol can also
bind to and activate the mineralocorticoid receptor (MR), a process that can be inhibited by the action of
11HSD2. (b) This panel depicts the role of GR and GCs in the skin under various conditions. (1) Under
normal physiological conditions, there is a balance between proinflammatory/proproliferative mediators
and anti-inflammatory/anti-proliferative (pro-differentiative) factors in the skin. One such anti-
inflammatory/anti-proliferative factor is GC/GR signaling, as loss of GR in a genetically manipulated mouse
model results in basally elevated skin inflammation (Sevilla et al., 2013). (2) In inflammatory skin diseases
such as atopic dermatitis and psoriasis, proinflammatory (and proproliferative) mediators predominate. In
this case, treatment with exogenous GCs enhances anti-inflammatory/anti-proliferative effects to restore
balance and help resolve disease. (3) With aging, despite the fact that proinflammatory mediators are often
elevated, other changes (e.g., augmented activity of 11HSD1 activity to increase endogenous active
cortisol/corticosterone levels) lead to a predominance of anti-inflammation and anti-proliferation. (4) In the
case of skin cancer, neoplastic transformation results in non-responsiveness of cells to normal anti-
proliferative signals. Nevertheless, even under this condition, the anti-inflammatory/anti-proliferative
action of GC/GR continues, such that epidermal deletion of GR (in a genetically manipulated mouse
model) leads to increased susceptibility to tumor development (Latorre et al., 2013).
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Oral CCR5 Inhibitors to Prevent
HIV Transmission: The New
‘‘Morning-Before Pill’’?
Vincent Piguet1
In a recent study by Matsuzawa and colleagues, Maraviroc, a CCR5 inhibitor, was
used as pre-exposure prophylaxis against HIV-1 infection. The authors used
an ex vivo model of HIV transmission to study the distribution and effectiveness
of this HIV inhibitor in healthy volunteers. Strikingly, 3 days or more of oral
administration of Maraviroc to healthy volunteers conferred protection against
HIV infection to skin-derived Langerhans cells in the ex vivo system, suggesting
Maraviroc as a useful candidate for pre-exposure prophylaxis in clinical trials.
Journal of Investigative Dermatology (2013) 133, 2662–2663. doi:10.1038/jid.2013.383
HIV infection remains a major threat to
global health. Despite years of intensive
research, HIV transmission continues to
occur at high rates in many areas of
the world. To curb HIV transmission,
several strategies such as circumcision,
vaccines, microbicides, and pre-expo-
sure prophylaxis (Pr-EP) have been
explored. Although vaccines are likely
to be the best hope of preventing HIV
transmission, there is still a long road
before a successful vaccine becomes
available (Haynes and McElrath, 2013).
In that context, alternative strategies
should be considered. One strategy is
to apply a substance to the skin that
prevents viral transmission, a micro-
bicide. Although significant advances
have been obtained in the field of
microbicides (Abdool Karim et al.
(2010), reviewed in Nikolic and Piguet
(2010); Haase (2011)), there is still no
effective regimen that prevents HIV
transmission. Another approach, some-
what similar to the morning-after
contraceptive pill, would be to give an
oral inhibitor of HIV before exposure,
thereby conferring Pr-EP.
In the article by Matsuzawa et al.
(2013), the authors report an elegant
study that sought to determine whether
oral administration of a CCR5 inhibitor
(Maraviroc) would be able to block HIV
interaction with Langerhans cells (LCs).
They used an ex vivo model to study LC
infection by HIV-1 and subsequent
transmission to CD4þ T cells. This
model allowed them to explore several
of the unidentified steps in Pr-EP against
HIV-1 by using a CCR5 inhibitor.
Dendritic cells (DCs) and their sub-
sets, such as LCs, are thought to be
important early cellular targets of HIV-
1 infection during the initial steps of HIV
transmission. The skin and mucosal
tissues contain different DC subsets that
have been differentiated according to
their anatomical location and cell sur-
face receptor expression. LCs specifi-
cally express the C-type lectin receptor
(CLR) CD207 (Langerin), and they reside
primarily in the epidermis. Dermal DC
subsets, some of which express the
C-type lectin CD209 (DC-SIGN), are
present throughout the dermis. One of
the hallmarks of these different DC
subsets is their specific expression of
different sets of CLR, pathogen recogni-
tion receptors, and chemokine receptors
(such as CCR5), ordinarily allowing DCs
to capture and detect incoming patho-
gens. DCs have a pivotal role during
antigen presentation, and they link
innate immunity with adaptive immu-
nity. In addition to their immune func-
tion, owing to their location in the
epithelia (in particular the genital
epithelia), LC and other DC subsets
See related article on pg 2803
1Department of Dermatology and Wound Healing, Institute of Infection and Immunity, School of
Medicine, Cardiff University, Cardiff, UK
Correspondence: Vincent Piguet, Department of Dermatology and Wound Healing, Institute of Infection
and Immunity, 3rd Floor, Glamorgan House, Cardiff University and University Hospital of Wales, Heath
Park, Cardiff CF14 4XN, UK. E-mail: piguetv@cardiff.ac.uk
COMMENTARY
2662 Journal of Investigative Dermatology (2013), Volume 133
